Text Size

Pharmacological Modulation of Cocaine Effects - 1

This study has been completed.
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000201
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.


Condition Intervention Phase
Cocaine-Related Disorders
 Drug: Selegiline
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacological Modulation of Cocaine Effects

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
Estimated Study Completion Date: December 2001
  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000201

Locations
United States, Maryland
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Investigators
Principal Investigator: George Bigelow, Ph.D. Johns Hopkins University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000201     History of Changes
Other Study ID Numbers: NIDA-05196-1, R01-05196-1
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Selegiline
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Central Nervous System Agents
Therapeutic Uses
Antiparkinson Agents
Anti-Dyskinesia Agents

ClinicalTrials.gov processed this record on May 23, 2013